CR20150638A - Marcador para trastornos de la esfingomielinasa ácida y sus usos - Google Patents
Marcador para trastornos de la esfingomielinasa ácida y sus usosInfo
- Publication number
- CR20150638A CR20150638A CR20150638A CR20150638A CR20150638A CR 20150638 A CR20150638 A CR 20150638A CR 20150638 A CR20150638 A CR 20150638A CR 20150638 A CR20150638 A CR 20150638A CR 20150638 A CR20150638 A CR 20150638A
- Authority
- CR
- Costa Rica
- Prior art keywords
- disorders
- acid sphingomyelinase
- marker
- asm
- treatment
- Prior art date
Links
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 title abstract 4
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 title abstract 4
- 239000003550 marker Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000014060 Niemann-Pick disease Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832302P | 2013-06-07 | 2013-06-07 | |
| PCT/US2014/041405 WO2014197859A1 (en) | 2013-06-07 | 2014-06-06 | Marker for acid sphingomyelinase disorders and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150638A true CR20150638A (es) | 2016-02-08 |
Family
ID=51062988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150638A CR20150638A (es) | 2013-06-07 | 2015-12-04 | Marcador para trastornos de la esfingomielinasa ácida y sus usos |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10022428B2 (enExample) |
| EP (2) | EP3584580A1 (enExample) |
| JP (4) | JP6457501B2 (enExample) |
| KR (3) | KR102292298B1 (enExample) |
| CN (2) | CN115128287A (enExample) |
| AU (5) | AU2014274670B2 (enExample) |
| CA (1) | CA2914751C (enExample) |
| CL (1) | CL2015003563A1 (enExample) |
| CR (1) | CR20150638A (enExample) |
| DK (1) | DK3004896T3 (enExample) |
| EA (1) | EA035342B1 (enExample) |
| ES (1) | ES2762608T3 (enExample) |
| HR (1) | HRP20192246T1 (enExample) |
| HU (1) | HUE047863T2 (enExample) |
| IL (3) | IL284102B2 (enExample) |
| LT (1) | LT3004896T (enExample) |
| MA (1) | MA38638B1 (enExample) |
| MX (1) | MX370570B (enExample) |
| MY (1) | MY185990A (enExample) |
| NZ (1) | NZ754328A (enExample) |
| PH (1) | PH12015502687A1 (enExample) |
| PL (1) | PL3004896T3 (enExample) |
| PT (1) | PT3004896T (enExample) |
| RS (1) | RS59677B1 (enExample) |
| SG (2) | SG10201709925SA (enExample) |
| SI (1) | SI3004896T1 (enExample) |
| UA (1) | UA120591C2 (enExample) |
| WO (1) | WO2014197859A1 (enExample) |
| ZA (1) | ZA201508630B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102094253B1 (ko) * | 2009-08-28 | 2020-03-31 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법 |
| PL3004896T3 (pl) * | 2013-06-07 | 2020-04-30 | Genzyme Corporation | Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania |
| JP6984854B2 (ja) * | 2015-10-08 | 2021-12-22 | 国立大学法人千葉大学 | ニーマン・ピック病ｃ型を予防または治療するための医薬組成物 |
| SG11202001544VA (en) * | 2017-08-24 | 2020-03-30 | Sanofi Sa | Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| JP7568648B2 (ja) * | 2019-05-31 | 2024-10-16 | ジェンザイム・コーポレーション | 二次元ｌｃ－ｍｓ／ｍｓシステム |
| EP4562432A2 (en) * | 2022-07-28 | 2025-06-04 | Wylder Nation Foundation | Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039388A (en) | 1976-06-04 | 1977-08-02 | The United States Of America As Represented By The Government | Diagnostic test for Niemann-Pick disease |
| US4082781A (en) | 1976-06-04 | 1978-04-04 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide |
| US5773278A (en) * | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| WO2002018539A2 (en) | 2000-08-25 | 2002-03-07 | Lysometrix Corporation | Method for assaying the activity of lysosomal enzymes |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US7615224B2 (en) | 2004-12-02 | 2009-11-10 | Women's And Children's Hospital | Multiplex-bead complex for determination of lysosomal storage disorders |
| JP2006214731A (ja) * | 2005-02-01 | 2006-08-17 | Institute Of Physical & Chemical Research | スフィンゴミエリンの検出方法 |
| CA2634042A1 (en) | 2005-12-15 | 2007-07-12 | The Research Foundation Of State University Of New York | Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine |
| AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| US8026099B2 (en) | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
| US8497122B2 (en) | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
| KR102094253B1 (ko) * | 2009-08-28 | 2020-03-31 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법 |
| JP2013002933A (ja) | 2011-06-16 | 2013-01-07 | Hitachi Plant Technologies Ltd | ３次元測位システム |
| JP6243846B2 (ja) * | 2011-11-15 | 2017-12-06 | セントジーン アーゲー | ニーマン・ピック病の診断のための方法 |
| WO2014183873A1 (en) * | 2013-05-14 | 2014-11-20 | Centogene Ag | Method for the diagnosis of niemann-pick disease |
| PL3004896T3 (pl) * | 2013-06-07 | 2020-04-30 | Genzyme Corporation | Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania |
-
2014
- 2014-06-06 PL PL14735056T patent/PL3004896T3/pl unknown
- 2014-06-06 EP EP19191053.8A patent/EP3584580A1/en active Pending
- 2014-06-06 IL IL284102A patent/IL284102B2/en unknown
- 2014-06-06 CA CA2914751A patent/CA2914751C/en active Active
- 2014-06-06 KR KR1020217007269A patent/KR102292298B1/ko active Active
- 2014-06-06 EA EA201592265A patent/EA035342B1/ru not_active IP Right Cessation
- 2014-06-06 LT LTEP14735056.5T patent/LT3004896T/lt unknown
- 2014-06-06 KR KR1020217025969A patent/KR102434244B1/ko active Active
- 2014-06-06 HU HUE14735056A patent/HUE047863T2/hu unknown
- 2014-06-06 EP EP14735056.5A patent/EP3004896B1/en active Active
- 2014-06-06 WO PCT/US2014/041405 patent/WO2014197859A1/en not_active Ceased
- 2014-06-06 ES ES14735056T patent/ES2762608T3/es active Active
- 2014-06-06 SG SG10201709925SA patent/SG10201709925SA/en unknown
- 2014-06-06 NZ NZ754328A patent/NZ754328A/en unknown
- 2014-06-06 DK DK14735056.5T patent/DK3004896T3/da active
- 2014-06-06 JP JP2016518053A patent/JP6457501B2/ja active Active
- 2014-06-06 RS RS20191627A patent/RS59677B1/sr unknown
- 2014-06-06 CN CN202210555370.6A patent/CN115128287A/zh active Pending
- 2014-06-06 MY MYPI2015704368A patent/MY185990A/en unknown
- 2014-06-06 CN CN201480043918.2A patent/CN105474017A/zh active Pending
- 2014-06-06 PT PT147350565T patent/PT3004896T/pt unknown
- 2014-06-06 AU AU2014274670A patent/AU2014274670B2/en active Active
- 2014-06-06 SI SI201431434T patent/SI3004896T1/sl unknown
- 2014-06-06 US US14/895,472 patent/US10022428B2/en active Active
- 2014-06-06 HR HRP20192246TT patent/HRP20192246T1/hr unknown
- 2014-06-06 KR KR1020167000011A patent/KR102228367B1/ko active Active
- 2014-06-06 UA UAA201600158A patent/UA120591C2/uk unknown
- 2014-06-06 MX MX2015016844A patent/MX370570B/es active IP Right Grant
- 2014-06-06 MA MA38638A patent/MA38638B1/fr unknown
- 2014-06-06 SG SG11201509622WA patent/SG11201509622WA/en unknown
-
2015
- 2015-11-23 ZA ZA2015/08630A patent/ZA201508630B/en unknown
- 2015-12-01 PH PH12015502687A patent/PH12015502687A1/en unknown
- 2015-12-04 CR CR20150638A patent/CR20150638A/es unknown
- 2015-12-04 CL CL2015003563A patent/CL2015003563A1/es unknown
- 2015-12-06 IL IL242964A patent/IL242964B/en unknown
-
2018
- 2018-02-09 AU AU2018200977A patent/AU2018200977B2/en active Active
- 2018-06-08 US US16/003,598 patent/US10888607B2/en active Active
- 2018-12-19 JP JP2018236856A patent/JP6835806B2/ja active Active
-
2020
- 2020-10-22 AU AU2020257114A patent/AU2020257114B2/en active Active
- 2020-12-11 US US17/119,035 patent/US11998592B2/en active Active
-
2021
- 2021-02-03 JP JP2021015390A patent/JP7414750B2/ja active Active
-
2022
- 2022-11-29 IL IL298675A patent/IL298675B2/en unknown
-
2023
- 2023-02-23 AU AU2023201062A patent/AU2023201062B2/en active Active
- 2023-12-27 JP JP2023220385A patent/JP2024038145A/ja active Pending
-
2024
- 2024-04-29 US US18/649,453 patent/US20240398907A1/en active Pending
-
2025
- 2025-08-25 AU AU2025220876A patent/AU2025220876A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150638A (es) | Marcador para trastornos de la esfingomielinasa ácida y sus usos | |
| ECSP22051489A (es) | Compuestos inhibidores de metaloenzimas | |
| CY1123735T1 (el) | Φαρμακευτικη χρηση toy fam19a5 που εμπλεκεται στη ρυθμιση γλοιογενησης | |
| CL2019001088A1 (es) | Nuevos anticuerpos monoclonales cd47 y sus usos. | |
| CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
| UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
| EP3825419A3 (en) | Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine | |
| MX2016004340A (es) | Compuestos heterociclicos y usos de los mismos. | |
| UY35472A (es) | Compuestos y sus usos en la modulacion de la hemoglobina | |
| BR112014029346A2 (pt) | sistema e método implementado por computador para a montagem de um plano de tratamento médico | |
| CL2014002265A1 (es) | Método, aparato y sistema para diagnóstico y tratamiento de un trastorno del estado del ánimo, el cual permite aplicar estimulación vestibular giratoria, calórica u optocinética a un individuo. | |
| BR112017026709A2 (pt) | tratamento e diagnóstico de câncer | |
| BR112015004465A2 (pt) | sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem | |
| BR112016003381A8 (pt) | sistema para administrar uma formulação de cantaridina a um indivíduo; dispositivo aplicador para administrar uma formulação de cantaridina a um indivíduo; usos de uma formulação de cantaridina; kit para administrar uma formulação de cantaridina a um indivíduo; formulações; e formulação de cantaridina | |
| EA201691314A1 (ru) | Терапевтические способы и композиции | |
| MX375145B (es) | Matrices detectables, sistemas para el diagnóstico y sus métodos de preparación y uso. | |
| BR112018001814B8 (pt) | Unidade de contêiner médica para planejamento e/ou fabricação de um implante específicos de paciente, anatomicamente adaptados | |
| BR112018003238A2 (pt) | seleção de pacientes para terapia de combinação | |
| UY35438A (es) | Procedimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| BR112017014416A2 (pt) | sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo | |
| BR112015024860A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose |